Remembering the forgotten non-communicable diseases

BMC Medicine

Cleusa P Ferri⁵  George Koob⁹  Nora D Volkow^1,10  Jürgen Rehm¹  Peter GJ Burney²  Jasvinder A Singh⁴  Marcello Tonelli⁷  Adeera Levin⁸  Thomas N Williams⁶  Alan D Lopez³ 

[1] Institute of Medical Science, UofT, Toronto, Canada;National Heart and Lung Institute, Imperial College, London, UK;School of Population and Global Health, The University of Melbourne, Building 379, 207 Bouverie St, Carlton, Melbourne 3053, VIC, Australia;Department of Orthopedic Surgery, Mayo Clinic College of Medicine, 200 1st St SW, Rochester 55905, MN, USA;Department of Psychobiology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu, 862- 1o andar, São Paulo 04023-062, CEP, Brazil;KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya;7th Floor, TRW Building, 3280 Hospital Drive NW, Calgary T2N 4Z6, Alberta, Canada;University of British Columbia, St Paul’s Hospital, 1081 Burrard Street Rm 6010 A, Vancouver V6Z1Y8, BC, Canada;National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda 20892-9304, MD, USA;National Institute on Drug Abuse, National Institutes of Health, Rockville, MD, USA

关键词: Liver cirrhosis;    Alcohol;    Substance abuse;    Gout;    Dementia;    Asthma;    Chronic kidney disease;    Sickle cell disease;    Non-communicable diseases;    Global health;   

Others  :  1118407
DOI  :  10.1186/s12916-014-0200-8

 received in 2014-10-03, accepted in 2014-10-03,  发布年份 2014

【 摘 要 】

The forthcoming post-Millennium Development Goals era will bring about new challenges in global health. Low- and middle-income countries will have to contend with a dual burden of infectious and non-communicable diseases (NCDs). Some of these NCDs, such as neoplasms, COPD, cardiovascular diseases and diabetes, cause much health loss worldwide and are already widely recognised as doing so. However, 55% of the global NCD burden arises from other NCDs, which tend to be ignored in terms of premature mortality and quality of life reduction. Here, experts in some of these ‘forgotten NCDs’ review the clinical impact of these diseases along with the consequences of their ignoring their medical importance, and discuss ways in which they can be given higher global health priority in order to decrease the growing burden of disease and disability.

【 授权许可】

   
2014 Lopez et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

Figure 11.

Figure 12.

Figure 13.

Figure 14.

【 参考文献 】

• [1]Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C, Naghavi M, Salomon JA, Shibuya K, Vos T, Wikler D, Lopez AD: GBD 2010: design, definitions, and metrics. Lancet 2012, 380:2063-2066.
• [2]Peto R, Lopez AD: The future worldwide health effects of current smoking patterns. In Tobacco and Public Health: Science and Policy. Edited by Boyle P, Gray N, Henningfield J, Safrin J, Zatonski W. Oxford University Press, Oxford; 2004:281-286.
• [3]Murray CJ, Lopez AD: Measuring the global burden of disease. N Engl J Med 2013, 369:448-457.
• [4]Grosse SD OI, Atrash HK, Amendah D, Piel FB, Williams TN: Sickle cell disease in Africa: a neglected cause of early child mortality. Am J Prev Med 2011, 41(6 Suppl 4):S398-405.
• [5]Rees DC, Williams TN, Gladwin MT: Sickle-cell disease. Lancet 2010, 376:2018-2031.
• [6][http://www.un.org/News/briefings/docs/2009/090619_Anaemia.doc.htm] webcite United Nations press office. Press conference on raising awareness of sickle-cell anaemia: []
• [7]World Health Organization Regional Office for Africa: Sickle-cell disease: a strategy for the WHO African Region. Report of the Regional Director. AFR/RC60/8. 2010.
• [8]Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Williams TN, Weatherall DJ, Hay SI: Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis.Nat Commun 2010, 1:104.
• [9]Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, et al.: A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2224-2260.
• [10]Ndila C, Bauni E, Nyirongo V, Mochamah G, Makazi A, Kosgei P, Nyutu G, Macharia A, Kapesa S, Byass P, Williams TN: Verbal autopsy as a tool for identifying children dying of sickle cell disease: a validation study conducted in Kilifi district, Kenya.BMC Med 2014, 12:65.
• [11]Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN: Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality, and interventions.Plos Med 2013, 10:e1001484.
• [12]Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, Temperley WH, Williams TN, Weatherall DJ, Hay SI: Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013, 381(9861):142-151.
• [13]Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basanez MG, Baxter A, Bell ML, Benjamin EJ, et al.: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-2223.
• [14]Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basanez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, et al.: Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2163-2196.
• [15]Telfer P, Coen P, Chakravorty S, Wilkey O, Evans J, Newell H, Smalling B, Amos R, Stephens A, Rogers D, Kirkham F: Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica 2007, 92:905-912.
• [16]Quinn CT, Rogers ZR, McCavit TL, Buchanan GR: Improved survival of children and adolescents with sickle cell disease. Blood 2010, 115:3447-3452.
• [17]Wierenga KJ, Hambleton IR, Lewis NA: Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet 2001, 357:680-683.
• [18]Ware RE: Is sickle cell anemia a neglected tropical disease?PLoS Negl Trop Dis 2013, 7:e2120.
• [19]Amendah DD, Mukamah G, Komba A, Ndila C, Williams TN: Routine paediatric sickle cell disease (SCD) outpatient care in a rural Kenyan hospital: utilization and costs.PLoS One 2013, 8:e61130.
• [20]Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
• [21]Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW: Chronic kidney disease: global dimension and perspectives. Lancet 2013, 382:260-272.
• [22]Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, et al.: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
• [23]Levin A, Chaudhry MR, Djurdjev O, Beaulieu M, Komenda P: Diabetes, kidney disease and cardiovascular disease patients. Assessing care of complex patients using outpatient testing and visits: additional metrics by which to evaluate health care system functioning. Nephrol Dial Transplant 2009, 24:2714-2720.
• [24]Manns BJ, Mendelssohn DC, Taub KJ: The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. Int J Health Care Finance Econ 2007, 7:149-169.
• [25][www.AKDN.info] webcite Alberta Kidney Disease Network:.
• [26][www.bcrenalagency.ca] webcite The BC Renal Agency:.
• [27][http://www.cann-net.ca/] webcite Advancing Kidney Care and Research in Canada: Available at: .
• [28]Matsushita K, Ballew SH, Astor BC, Jong PE, Gansevoort RT, Hemmelgarn BR, Levey AS, Levin A, Wen CP, Woodward M, Coresh J: Cohort profile: the Chronic Kidney Disease Prognosis Consortium. Int J Epidemiol 2013, 42:1660-1668.
• [29]Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS, Consortium CKDP: Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014, 311:2518-2531.
• [30]Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, Woolf A, March L: The global burden of gout: estimates from the Global Burden of Disease 2010 study.Ann Rheum Dis 2014,
• [31]Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE: Epidemiology of gout: is the incidence rising? J Rheumatol 2002, 29:2403-2406.
• [32]Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R: Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004, 31:1582-1587.
• [33]Zhu Y, Pandya BJ, Choi HK: Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011, 63:3136-3141.
• [34]Choi HK: A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol 2010, 22:165-172.
• [35]Zhang Y, Chen C, Choi H, Chaisson C, Hunter D, Niu J, Neogi T: Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis 2012, 71:1448-1453.
• [36]Zhang Y, Woods R, Chaisson CE, Neogi T, Niu J, McAlindon TE, Hunter D: Alcohol consumption as a trigger of recurrent gout attacks.Am J Med 2006, 119:800. e813-808.
• [37]Singh JA: Research priorities in gout: the patient perspective. J Rheumatol 2014, 41:615-616.
• [38]Singh JA: The Impact of Gout on Patient’s Lives and Differences by Gender and Race: A Patient Perspective.Arthritis Res Ther 2014,
• [39]Malik A, Schumacher HR, Dinnella JE, Clayburne GM: Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol 2009, 15:22-24.
• [40]Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, et al.: 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012, 64:1431-1446.
• [41]Dalbeth N, House ME, Horne A, Petrie KJ, McQueen FM, Taylor WJ: Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.BMC Musculoskelet Disord 2012, 13:174.
• [42]Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW: Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006, 12:61-65.
• [43]Singh JA, Hodges JS, Asch SM: Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis 2009, 68:1265-1270.
• [44]Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C: Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009, 36:1273-1282.
• [45]Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR: The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 2009, 15:3-7.
• [46]Shoji A, Yamanaka H, Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004, 51:321-325.
• [47][http://www.aspenpharma.com.au/product_info/pi/PI_Zyloprim.pdf] webcite Product Information. Zylorim™ (Allopurinol) tablets:.
• [48]Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT: Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011, 63:412-421.
• [49]Longo G, Strinati R, Poli F, Fumi F: Genetic factors in nonspecific bronchial hyperreactivity. An epidemiologic study. Am J Dis Child 1987, 141:331-334.
• [50]Sibbald B: T-WM: Factors influencing the prevalence of asthma among first degree relatives of extrinsic and intrinsic asthmatics. Thorax 1979, 34:332-337.
• [51]Weinmayr G, Weiland SK, Bjorksten B, Brunekreef B, Buchele G, Cookson WO, Garcia-Marcos L, Gotua M, Gratziou C, van Hage M, von Mutius E, Riikjarv MA, Rzehak P, Stein RT, Strachan DP, Tsanakas J, Wickens K, Wong GW, Group IPTS: Atopic sensitization and the international variation of asthma symptom prevalence in children. Am J Respir Crit Care Med 2007, 176:565-574.
• [52]Law MMJ, Wald N, Luczynska C, Burney P: Changes in atopy over a quarter of a century, based on cross sectional data at three time periods. BMJ 2005, 330:1187-1188.
• [53]Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, Williams H, Group IPTS: Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006, 368:733-743.
• [54]Asher MI, Pattemore PK, Harrison AC, Mitchell EA, Rea HH, Stewart AW, Woolcock AJ: International comparison of the prevalence of asthma symptoms and bronchial hyperresponsiveness. Am Rev Respir Dis 1988, 138:524-529.
• [55]Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S: Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2009, 64:476-483.
• [56]Sembajwe G, Cifuentes M, Tak SW, Kriebel D, Gore R, Punnett L: National income, self-reported wheezing and asthma diagnosis from the World Health Survey. Eur Respir J 2010, 35:279-286.
• [57]Van Niekerk CH, Weinberg EG, Shore SC, Heese HV, Van Schalkwyk J: Prevalence of asthma: a comparative study of urban and rural Xhosa children. Clin Allergy 1979, 9:319-314.
• [58]Keeley DJ, Neill P, Gallivan S: Comparison of the prevalence of reversible airways obstruction in rural and urban Zimbabwean children. Thorax 1991, 46:549-553.
• [59]Calvert J, Burney P: Ascaris, atopy, and exercise-induced bronchoconstriction in rural and urban South African children. J Allergy Clin Immunol 2010, 125:100-105. e101-105
• [60]Obaseki D, Potts J, Joos G, Baelum J, Haahtela T, Ahlstrom M, Matricardi P, Kramer U, Gjomarkaj M, Fokkens W, Makowska J, Todo-Bom A, Toren K, Janson C, Dahlen SE, Forsberg B, Jarvis D, Howarth P, Brozek G, Minov J, Bachert C, Burney P: The relation of airway obstruction to asthma, chronic rhinosinusitis and age: results from a population survey of adults. Allergy 2014, 69:1205-1214.
• [61][http://www.ginasthma.org/] webcite Asthma GGIf: Available at:. Accessed 6/20, 2014.
• [62]Ait-Khaled NED, Bissell K, Billo NE: Access to inhaled corticosteroids is key to improving quality of care for asthma in developing countries. Allergy 2007, 62:230-236.
• [63]Burney P, Potts J, Ait-Khaled N, Sepulveda RM, Zidouni N, Benali R, Jerray M, Musa OA, El-Sony A, Behbehani N, El-Sharif N, Mohammad Y, Khouri A, Paralija B, Eiser N, Fitzgerald M, Abu-Laban R: A multinational study of treatment failures in asthma management. Int J Tuberc Lung Dis 2008, 12:13-18.
• [64][http://www.who.int/healthinfo/global_burden_disease/estimates_regional/en/] webcite WHO causes of death 2000 – 2011:.
• [65][http://www.who.int/healthinfo/global_burden_disease/projections/en/] webcite WHO projections for 2015 and 2030:.
• [66]Talwalkar JA, Kamath PS: Influence of recent advances in medical management on clinical outcomes of cirrhosis. Mayo Clin Proc 2005, 80:1501-1508.
• [67]Liang W, Chikritzhs T, Pascal R, Binns CW: Mortality rate of alcoholic liver disease and risk of hospitalization for alcoholic liver cirrhosis, alcoholic hepatitis and alcoholic liver failure in Australia between 1993 and 2005. Intern Med 2011, 41:34-41.
• [68]Roberts SE, Goldacre MJ, Yeates D: Trends in mortality after hospital admission for liver cirrhosis in an English population from 1968 to 1999. Gut 2005, 54:1615-1621.
• [69]Schmidt LA, Mäkelä P, Rehm J, Room R: Alcohol: equity and social determinants. In Equity, Social Determinants and Public Health Programmes. Edited by Blas E, Kurup AS. World Health Organization, Geneva, Switzerland; 2010:11-29.
• [70]Rehm J, Samokhvalov AV, Shield KD: Global burden of alcoholic liver diseases. J Hepatol 2013, 59:160-168.
• [71]Global status report on alcohol and health. World Health Organization, Geneva, Switzerland; 2014.
• [72]Rehm J, Taylor B, Mohapatra S, Irving H, Baliunas D, Patra J, Roerecke M: Alcohol as a risk factor for liver cirrhosis - a systematic review and meta-analysis. Drug Alcohol Rev 2010, 29:437-445.
• [73]Vernon G, Baranova A, Younossi ZM: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
• [74]Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.J Hepatol 2006, 45:
• [75]Zatonski W, Sulkowska U, Manczuk M, Rehm J, Lowenfels AB, La Vecchia C: Liver cirrhosis mortality in Europe, with special attention to central and eastern Europe. Eur Addict Res 2010, 16:193-201.
• [76]Ye Y, Kerr WC: Alcohol and liver cirrhosis mortality in the United States: comparison of methods for the analyses of time-seriespanel data models. Alcohol Clin Exp Res 2011, 35:108-115.
• [77]Leon DA, Chenet L, Shkolnikov V, Zakharov S, Shapiro J, Rakhmanova G, Vassin S, McKee M: Huge variation in Russian mortality rates 1984–1994: artefact, alcohol, or what? Lancet 1997, 350:383-388.
• [78]Pridemore WA, Chamlin MB, Kaylen MT, Andreev E: The effects of the, Russian alcohol policy on alcohol-related mortality: an interrupted time series analysis. Alcohol Clin Exp Res 2006, 2014:257-266.
• [79]Fillmore KM, Roizen R, Farrell M, Kerr W, Lemmens P: Wartime Paris, cirrhosis mortality, and the ceteris paribus assumption. J Stud Alcohol 2002, 63:436-446.
• [80]Dills AK, Miron JA: Alcohol prohibition and Cirrhosis. Am L & Econ Rev 2004, 6:285-318.
• [81]Holmes J, Meier PS, Booth A, Guo Y, Brennan A: The temporal relationship between per capita alcohol consumption and harm: a systematic review of time lag specifications in aggregate time series analyses. Drug Alcohol Depend 2012, 123:7-14.
• [82]Babor T, Caetano R, Casswell S, Edwards G, Giesbrecht N, Graham K, Grube J, Gruenewald P, Hill L, Holder H, Homel R, Livingston M, Österberg E, Rehm J, Room R, Rossow I: Alcohol: No ordinary commodity. Research and public policy. 2nd edition. Oxford University Press, Oxford and London; 2010.
• [83]Rehm J, Shield KD, Rehm MX, Gmel G, Frick U: Modelling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol 2013, 23:89-97.
• [84]Rehm J, Roerecke M: Reduction of drinking in problem drinkers and all-cause mortality. Alcohol Alcohol 2013, 48:509-513.
• [85]Nutt DJ, Rehm J: Doing it by numbers: a simple approach to reducing the harms of alcohol. J Psychopharmacol 2014, 28:3-7.
• [86]Degenhardt LWH, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, Freedman G, Burstein R, Johns N, Engell RE, Flaxman A, Murray CJ, Vos T: Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1564-1574.
• [87][http:/ / www.unodc.org/ unodc/ en/ commissions/ CND/ session/ 57_Session_2014/ CND-57-Session_HLS-Statements.htm] webcite United Nations Office on Drugs and Crime:ᅟ.
• [88]Volkow ND, Wang GJ, Fowler JS, Tomasi D: Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol 2012, 52:321-336.
• [89]Amato LDM, Vecchi S, Ali R, Farrell M, Faggiano F, Foxcroft D, Ling W, Minozzi S, Chengzheng Z: Cochrane systematic reviews in the field of addiction: what's there and what should be. Drug Alcohol Depend 2011, 113:96-103.
• [90]Sousa RM, Ferri CP, Acosta D, Albanese E, Guerra M, Huang Y, Jacob KS, Jotheeswaran AT, Rodriguez JJ, Pichardo GR, Rodriguez MC, Salas A, Sosa AL, Williams J, Zuniga T, Prince M: Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. Lancet 2009, 374:1821-1830.
• [91]Sousa RMFC, Acosta D, Guerra M, Huang Y, Jacob K, Jotheeswaran A, Hernandez MA, Liu Z, Pichardo GR, Rodriguez JJ, Salas A, Sosa AL, Williams J, Zuniga T, Prince M: The contribution of chronic diseases to the prevalence of dependence among older people in Latin America, China and India: a 10/66 Dementia Research Group population-based survey.BMC Geriatr 2010, 10.
• [92]Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP: The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013, 9:63-75. e62
• [93]Wimo A, Jonsson L, Bond J, Prince M, Winblad B: Alzheimer Disease I: the worldwide economic impact of dementia 2010. Alzheimers Dement 2013, 9:1-11. e13
• [94]Rocca WA, Petersen RC, Knopman DS, Hebert LE, Evans DA, Hall KS, Gao S, Unverzagt FW, Langa KM, Larson EB, White LR: Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement 2011, 7:80-93.
• [95]Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L, Brayne C: A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 2013, 382:1405-1412.
• [96]Qiu C, von Strauss E, Backman L, Winblad B, Fratiglioni L: Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology 2013, 80:1888-1894.
• [97]Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM: Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology 2012, 78:1456-1463.
• [98]Stampfer MJ: Cardiovascular disease and Alzheimer's disease: common links. J Intern Med 2006, 260:211-223.
• [99]Lincoln P, Fenton K, Alessi C, Prince M, Brayne C, Wortmann M, Patel K, Deanfield J, Mwatsama M: The Blackfriars Consensus on brain health and dementia. Lancet 2014, 383:1805-1806.
• [100]Jagger C, Matthews R, Lindesay J, Robinson T, Croft P, Brayne C: The effect of dementia trends and treatments on longevity and disability: a simulation model based on the MRC Cognitive Function and Ageing Study (MRC CFAS). Age Ageing 2009, 38:319-325. discussion 251
• [101]Barnes DE, Yaffe K: The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011, 10:819-828.
• [102]Norton SMF, Barnes DE, Yaffe K, Brayne C: Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol 2014, 13:788-794.